Clinical Trials
8 trialsNCT01662804 2021-05-27
Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01576692 2018-11-15
Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02130869 2017-12-22
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01404702 2014-12-02
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
University of Alabama at Birmingham
Phase 1 Terminated
NCT00054405 2013-04-09
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00005576 2013-01-16
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002748 2011-10-04
Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed
NCT00186862 2008-06-03
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma
St. Jude Children's Research Hospital
Phase 1 Completed